Clicky

CytomX Therapeutics, Inc.(CTMX)

Description: CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., and ImmunoGen, Inc. to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.


Keywords: Life Sciences Monoclonal Antibody Therapy Compugen Immunogen Oncology Focused Biopharmaceutical

Home Page: www.cytomx.com

CTMX Technical Analysis

151 Oyster Point Boulevard
South San Francisco, CA 94080
United States
Phone: 650 515 3185


Officers

Name Title
Dr. Sean A. McCarthy D.Phil., DPHIL Chairman & CEO
Mr. Lloyd A. Rowland Jr., J.D. Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.
Mr. Christopher W. Ogden Sr. VP of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer
Dr. Chau Cheng M.B.A., Ph.D. VP of Investor Relations & Corp. Communications
Ms. Danielle Olander-Moghadassian Sr. VP & Chief HR Officer
Ms. Leslie Robbins Sr. VP of Intellectual Property
Dr. Marcia P. Belvin Ph.D. Sr. VP & Head of Research
Mr. Jeffrey Landau B.S., M.B.A. Sr. VP, Head of Strategy & Chief Bus. Officer
Dr. Jamie Moore Ph.D. Sr. VP & Head of Protein and Process Sciences and Manufacturing
Dr. Hoyoung Huh M.D., Ph.D. Special Advisor to Chief Exec. Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.8062
Price-to-Sales TTM: 1.4467
IPO Date: 2015-10-08
Fiscal Year End: December
Full Time Employees: 174
Back to stocks